Back to Search
Start Over
Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes.
- Source :
-
Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2002 Feb 01; Vol. 168 (3), pp. 1154-66. - Publication Year :
- 2002
-
Abstract
- Fas (APO-1/CD95) and its ligand (FasL/CD95L) are cell surface proteins whose interaction activates apoptosis of Fas-expressing targets. In T lymphocytes, the Fas/FasL system regulates activation-induced cell death, a fundamental mechanism for negative selection of immature T cells in the thymus and for maintenance of peripheral tolerance. Aberrant expression of Fas and FasL has also been implicated in diseases in which the lymphocyte homeostasis is compromised, and several studies have described the pathogenic functions of Fas and FasL in vivo, particularly in the induction/regulation of organ-specific autoimmune diseases. The 1,25(OH)(2)D(3) is a secosteroid hormone that activates the nuclear receptor vitamin D(3) receptor (VDR), whose immunosuppressive activities have been well studied in different models of autoimmune disease and in experimental organ transplantation. We and others have recently described the molecular mechanisms responsible for the negative regulation of the IFN-gamma and IL-12 genes by 1,25(OH)(2)D(3) in activated T lymphocytes and macrophages/dendritic cells. In this study, we describe the effect of 1,25(OH)(2)D(3) on the activation of the fasL gene in T lymphocytes. We show that 1,25(OH)(2)D(3) inhibits activation-induced cell death, fasL mRNA expression, and that 1,25(OH)(2)D(3)-activated VDR represses fasL promoter activity by a mechanism dependent on the presence of a functional VDR DNA-binding domain and ligand-dependent transcriptional activation domain (AF-2). Moreover, we identified a minimal region of the promoter containing the transcription start site and a noncanonical c-Myc-binding element, which mediates this repression. These results place FasL as a novel target for the immunoregulatory activities of 1,25(OH)(2)D(3), and confirm the interest for a possible pharmacological use of this molecule and its derivatives.
- Subjects :
- Animals
Cell Death drug effects
Cell Death immunology
Cytotoxicity, Immunologic drug effects
Cytotoxicity, Immunologic genetics
DNA-Binding Proteins genetics
DNA-Binding Proteins physiology
Down-Regulation drug effects
Fas Ligand Protein
Humans
Hybridomas cytology
Hybridomas drug effects
Hybridomas immunology
Jurkat Cells
Lymphocyte Activation drug effects
Lymphocyte Activation genetics
Membrane Glycoproteins biosynthesis
Membrane Glycoproteins physiology
Mice
Point Mutation
Promoter Regions, Genetic drug effects
Promoter Regions, Genetic immunology
Protein Structure, Tertiary drug effects
Protein Structure, Tertiary genetics
Protein Structure, Tertiary physiology
Receptors, Calcitriol genetics
Receptors, Calcitriol physiology
Regulatory Sequences, Nucleic Acid drug effects
Regulatory Sequences, Nucleic Acid immunology
Sequence Deletion immunology
Tumor Cells, Cultured
Cholecalciferol pharmacology
Down-Regulation genetics
Down-Regulation immunology
Immunosuppressive Agents pharmacology
Membrane Glycoproteins antagonists & inhibitors
Membrane Glycoproteins genetics
T-Lymphocytes drug effects
T-Lymphocytes immunology
Subjects
Details
- Language :
- English
- ISSN :
- 0022-1767
- Volume :
- 168
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Journal of immunology (Baltimore, Md. : 1950)
- Publication Type :
- Academic Journal
- Accession number :
- 11801650
- Full Text :
- https://doi.org/10.4049/jimmunol.168.3.1154